

**Press Release**

**Alembic Pharmaceuticals reports resilient Q4 FY26 performance**

**Revenue up 4%; Net Profit up 29% YoY**

**Vadodara, May 15<sup>th</sup>, 2026:** Alembic Pharmaceuticals Limited reported its consolidated financial results for the fourth quarter and year ended 31<sup>st</sup> March 2026.

**Financial Highlights for Q4 FY26**

- Revenue from operations increased by 4% YoY to Rs.1,848 Cr.
- Profit After Tax at Rs. 203 Cr, up 29% YoY
- EBITDA pre R&D increased by 8% YoY to Rs. 455 Cr; Pre R&D EBITDA margin stood at 25%

**Commenting on the results, Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, said,** *“Q4FY26 reflects disciplined execution across our businesses, supported by continued focus on profitability, operational delivery and long-term growth investments. We delivered revenue growth across key segments while maintaining healthy pre-R&D operating margins. During the quarter, we marked our entry into the Branded Business in the US, beginning with the launch of Pivya, opening a new avenue for long-term value creation.”*

**Operational Highlights**

**India Branded Business**

- India Branded Business delivered 4% YoY growth, reaching Rs 568 Cr. in revenue for the quarter.
- Gynaecology, Gastrology, Ophthalmology and Animal healthcare segments demonstrated encouraging performance during the quarter.
- 2 new products were introduced during the quarter.

**International Business**

- US Formulation grew by 11% to Rs. 564 Cr.
- 6 Launches in the US market during the quarter.
- Ex-US Generics recorded revenue of Rs. 369 Cr.
- 4 ANDA approvals received during the quarter

**ALEMBIC PHARMACEUTICALS LIMITED**

## Entry into US Branded Pharmaceuticals market

During the quarter, the Company launched its US branded business through Alembic Therapeutics, its step-down wholly owned subsidiary, with the commercial launch of Pivya®. This marks the first step in Alembic's strategy to build a focused branded specialty portfolio in the US.

Pivya® represents a first-line oral antibiotic option for the treatment of uncomplicated urinary tract infections (uUTIs) in women. The segment has seen limited new product introductions for more than a decade, creating an opportunity for a clinically established therapy with a strong safety and efficacy profile.

## API Business

- API business grew by 2% to Rs. 347 Cr.

The summary of Revenue from Operations is as under:

Particulars				(Rs in Cr.)		
	Q4 FY25	Q4 FY26	% Change	FY25	FY26	% Change
<b>Formulation</b>						
India	545	568	4%	2339	2458	5%
USA	508	564	11%	1957	2206	13%
Ex- US	375	369	-2%	1243	1494	20%
<b>API</b>	342	347	2%	1133	1187	5%
<b>Total</b>	<b>1770</b>	<b>1,848</b>	<b>4%</b>	<b>6672</b>	<b>7345</b>	<b>10%</b>

**Earnings Call:** Alembic Pharmaceuticals Limited will host an investor call at 5.00 pm IST on May 15, 2026, where the senior management will discuss the Company's performance and answer questions from participants. Please dial the numbers provided below ten minutes ahead of the scheduled start time to participate in this conference call. The dial-in number for this call is +91 22 6280 1411/ +91 22 7115 8312. Other toll numbers are listed in the conference call invitation, which is posted on

## ALEMBIC PHARMACEUTICALS LIMITED



the Company website [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com). The operator will provide instructions on asking questions before the start of the call.

### **About Alembic Pharmaceuticals Limited**

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded generics in India.

Information about the company can be found at [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com); (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

**For more information, contact:**

**Ajay Kumar Desai: Phone: +91 022- 66953681 Email: [ajay.desai@alembic.co.in](mailto:ajay.desai@alembic.co.in)**

## **ALEMBIC PHARMACEUTICALS LIMITED**

REGD. OFFICE: ALEMBIC ROAD, VADODARA - 390 003. • TEL: (0265) 2280550, 2280880 • FAX: (0265) 2281229  
Website : [www.alembicpharmaceuticals.com](http://www.alembicpharmaceuticals.com) • E-mail : [alembic@alembic.co.in](mailto:alembic@alembic.co.in) • CIN : L24230GJ2010PLC061123